The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index; 42 of the 115 sources its claims cite were checked for support.
Importance of FDA-Integrated Continuous Glucose Monitors to Ensure Accuracy of Continuous Glucose Monitoring
Open accessAbstract
Continuous glucose monitoring (CGM) has been shown to improve glycemic control and self-monitoring, as well as to reduce the risk of hypoglycemia. Integrated CGM (iCGM) FDA-cleared systems with published performance data are established nonadjunctive and accurate CGM tools that can directly inform decision-making in the treatment of diabetes (i.e., insulin dosing). Studies have assessed accuracy and safety data of CGMs that were eventually cleared for iCGM by the FDA and that informed the recommendation for their nonadjunctive use. Subsequent robust clinical trials and real-world studies demonstrated clinical effectiveness with improvements in a range of patient outcomes. In recent years, a number of non-iCGM-approved CGM devices have entered the market outside the United States worldwide. Some of these non-iCGM-approved CGM devices require additional user verification of blood glucose levels to be performed for making treatment decisions, termed adjunctive. Moreover, in many non-iCGM-approved CGM devices, accuracy studies published in peer-reviewed journals are scarce or have many limitations. Consequently, non-iCGM-approved CGM devices cannot be automatically perceived as having the same performance or quality standards than those approved for iCGM by the FDA. As a result, although these devices tend to cost less than iCGMs that carry FDA clearance and could therefore be attractive from the point of view of a health care payer, it must be emphasized that evaluation of costs should not be limited to the device (such as the usability preference that patients have for nonadjunctive sensors compared to adjunctive sensors) but to the wider value of the total benefit that the product provides to the patient.
Overview
CoChat Summary
TL;DR
This review argues that FDA-cleared integrated continuous glucose monitoring (iCGM) systems meet the strictest accuracy standard and should be distinguished from non-iCGM-approved devices marketed outside the United States. It contends that non-iCGM devices often lack robust published accuracy and outcome evidence, may require adjunctive blood glucose confirmation, and should not be assumed equivalent based on lower cost alone.
Key findings
- FDA iCGM special controls are described as the strictest CGM accuracy standard worldwide; the paper lists Abbott FreeStyle Libre 2, Libre 2 Plus, Libre 3, Libre 3 Plus, Dexcom G6, and Dexcom G7 as meeting iCGM requirements, with an addendum noting later iCGM designation for Senseonics Eversense.
- Table 1 iCGM performance requirements include, for example, lower one-sided 95% confidence bounds exceeding 85% for readings within ±15 mg/dL when <70 mg/dL, exceeding 70% for within ±15% when 70–180 mg/dL, exceeding 80% for within ±15% when >180 mg/dL, and exceeding 87% for within ±20% across the measuring range.
- Non-iCGM-approved devices outside the United States may have scarce or limited peer-reviewed accuracy studies; cited limitations include small samples (e.g., n < 100), high proportions of type 2 diabetes, adult-only studies despite indicated ages ≥2 years, few data in the critical <70 mg/dL range, and no glucose or insulin challenges.
- Cost comparisons should include total value—transmitters, readers, additional fingerstick tests, support services, and digital data security—not just device price; many non-iCGM-approved devices may be cheaper but are said to come up short in ease of use, technical performance, and manufacturer support.
Methods
- Narrative review comparing FDA iCGM special control performance requirements with quality standards of CGM systems, particularly non-iCGM-approved devices that entered markets outside the United States.
- Sources include FDA classification documents, Table 1 iCGM special controls, published accuracy studies, regulatory summaries, and prior reviews by Pemberton et al. and Freckmann et al.; no primary patient data or systematic search strategy is described.
- Main analysis is a narrative synthesis with tables summarizing iCGM performance requirements and FDA nonadjunctive CGM definitions alongside limitations of accuracy studies for non-iCGM-approved devices.
Limitations
- The paper does not explicitly state limitations.
- Evident: it is a narrative review without a described systematic search, formal risk-of-bias assessment, or meta-analysis, so selection of cited evidence may be selective.
- Evident: the comparison relies on FDA iCGM criteria and published/regulatory documents rather than independent primary accuracy testing of the devices discussed.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 1 Not valid · 18 Not checked · 11 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, in many non-iCGM-approved CGM devices, accuracy studies published in peer-reviewed journals are scarce or have many limitations.”
§ Importance of FDA-Integrated Continuous Glucose Monitors to Ensure Accuracy of Continuous Glucose Monitoring > Abstract
What the sources say
- Not checked yetcites [28] Pemberton JS Wilmot EG Barnard-Kelly K, et al. CGM accuracy: contrasting CE marking with the governmental controls of the USA (FDA) and Australia (TGA): a narrative review. Diabetes Obes Metab. 2023; 25(4): 916- 939. 36585365 source
- Partly supportedcites [29] Freckmann G Eichenlaub M Waldenmaier D, et al. Clinical performance evaluation of continuous glucose monitoring systems: a scoping review and recommendations for reporting. J Diabetes Sci Technol. 2023; 17(6): 1506- 1526. 37599389 PMC10658695 sourceExperimental — accuracy not yet measured
The Conclusion reports that CGM performance studies often omit crucial design information, and Limitations of This Review says few studies examined the same CGM system. These findings support concerns about study limitations and limited evidence for individual systems, but the paper does not establish that accuracy studies are scarce or limited specifically for many non-iCGM-approved devices. Page numbers are unavailable in our copy. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Some of these non-iCGM-approved CGM devices require additional user verification of blood glucose levels to be performed for making treatment decisions, termed adjunctive.”
§ Importance of FDA-Integrated Continuous Glucose Monitors to Ensure Accuracy of Continuous Glucose Monitoring > Abstract
What the sources say
- Supportedcites [12] Aleppo G Ruedy KJ Riddlesworth TD, et al. REPLACE-BG: a randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. Diabetes Care. 2017; 40(4): 538- 545. 28209654 PMC5864100 source
The Introduction states that CGM systems approved for adjunctive use required a blood glucose measurement to confirm the sensor reading before an insulin dosing decision. This supports the claim’s description of devices requiring additional verification for treatment decisions; the paper does not use the term “iCGM.” (LLM, conf=0.91)
- Not checked yetcites [13] U.S. Food and Drug Administration (FDA). News release: FDA expands indication for continuous glucose monitoring system, first to replace fingerstick testing for diabetes treatment decisions, 2016. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm534056.htm. Accessed October 8, 2023.
- Not checked yetcites [14] Food and Drug Administration (FDA). Non-adjunctive implanted glucose sensor. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?ID=QHJ#:~:text=A%20non%2Dadjunctive%20implanted%20glucose,make%20diabetes%2Drelated%20treatment%20decisions. Accessed February 29, 2024.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“For instance, accuracy studies published in peer-reviewed journals are not available for some devices, and the result is that their pivotal accuracy studies for regulatory clearance might not be replicated in independent studies.32,33”
§ Importance of FDA-Integrated Continuous Glucose Monitors to Ensure Accuracy of Continuous Glucose Monitoring > Introduction > Importance of an iCGM
What the sources say
- Could not verifycites [32] Klonoff DC Prahalad P. Performance of cleared blood glucose monitors. J Diabetes Sci Technol. 2015; 9(4): 895- 910. 25990294 PMC4525666 sourceExperimental — accuracy not yet measured
Our copy of Klonoff & Prahalad (2015) is a review of published performance of cleared blood glucose monitors: the Methods/Results (Performance of BGM Systems) report 11 PubMed-indexed publications covering 98 BGM systems, and the only statement about missing literature is that 'No publications were found that specifically addressed performance against FDA draft 2014' — a gap about a standard, not about particular devices lacking published accuracy studies. Nothing in the Discussion (which instead notes that a significant proportion of cleared BGMs do not perform at the level for which they were cleared, and describes FDA postmarket surveillance and the DTS postmarket BGM surveillance program) asserts that peer-reviewed accuracy studies are unavailable for some devices or that pivotal clearance studies go unreplicated. Searches for 'accuracy studies not available for some devices', 'pivotal/clearance studies not replicated', and CGM/iCGM literature returned no supporting passage; CGMs appear only as devices calibrated by BGMs (Clinical Risks). (LLM, conf=0.68)
- Partly supportedcites [33] Kolle J Eichenlaub M Mende J, et al. Performance assessment of three continuous glucose monitoring systems in adults with type 1 diabetes [published online ahead of print February 22, 2023]. J Diabetes Sci Technol. doi: 10.1177/19322968231159657. PMC11529083 37758681 sourceExperimental — accuracy not yet measured
The Introduction (device-selection paragraph) states that FL2 and ADX were chosen partly because of 'a lack of manufacturer-independent performance assessment in the scientific literature,' and the Discussion (FL2 paragraph) adds that theirs is 'the first manufacturer-independent performance evaluation' of FL2 — so our copy supports only that independent accuracy evaluations were missing for some devices, not that peer-reviewed accuracy studies were unavailable. In fact the same paper cites prior peer-reviewed accuracy publications for the devices it tested (Alva et al. ref 8 for FL2, Ji et al. ref 7 for ADX), and the claim's 'non-iCGM-approved' qualifier is absent: our copy mentions FDA 'integrated' CGM requirements only in the Figure 2 caption as the basis for the CG-DIVA deviation intervals, never as a device-approval category tied to literature availability. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, the body of evidence is scarce, insufficient, or even lacking for many non-iCGM-approved entrants, in terms not only of accuracy, but also of glycemic outcomes (i.e., time in range, time above range, time below range, coefficient of variation).20-23,29”
§ Importance of FDA-Integrated Continuous Glucose Monitors to Ensure Accuracy of Continuous Glucose Monitoring > Discussion
What the sources say
- Not checked yetcites [20] Rebec M Cai K Dutt-Ballerstadt R Anderson E. A prospective multicenter clinical performance evaluation of the C-CGM system. J Diabetes Sci Technol. 2022; 16(2): 390- 396. 33084416 PMC8861779 source
- Could not verifycites [21] Zhou J Zhang S Li L, et al. Performance of a new real-time continuous glucose monitoring system: a multicenter pilot study. J Diabetes Investig. 2018; 9(2): 286- 293. PMC5835467 28563974 sourceExperimental — accuracy not yet measured
The Discussion and Results report accuracy testing for the Medtrum RT-CGM system, but do not assess whether evidence is scarce for many non-iCGM-approved devices. Searches for evidence limitations and the specified glycemic outcomes found no passage addressing that broader claim. The indexed passages provide section labels but no page numbers. (LLM, conf=0.72)
- Partly supportedcites [22] Meng R Gu T Yang F Liu J Sun Q Zhu D. Performance evaluation of the Glunovo® continuous blood glucose monitoring system in Chinese participants with diabetes: a multicenter, self-controlled trial. Diabetes Ther. 2021; 12(12): 3153- 3165. 34704201 PMC8586329 sourceExperimental — accuracy not yet measured
The Methods (Study Outcomes) and Results (Primary Outcomes; page numbers unavailable) show that this paper evaluates Glunovo’s accuracy but does not report the listed glycemic outcomes. It does not assess whether evidence is scarce or insufficient across many non-iCGM-approved entrants, or establish that accuracy evidence is lacking for them. (LLM, conf=0.79)
- Partly supportedcites [23] Yan L Li Q Guan Q, et al. Evaluation of the performance and usability of a novel continuous glucose monitoring system. Int J Diabetes Dev Ctries. 2023; 43: 551- 558. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) describes the GS1 accuracy study as small and one-arm, calls for larger comparative studies, and says long-term effects on patients remain unconfirmed. This supports limited evidence for one device, but the paper does not assess whether evidence is scarce for many non-iCGM-approved entrants or report the listed glycemic outcomes. (LLM, conf=0.82)
- Partly supportedcites [29] Freckmann G Eichenlaub M Waldenmaier D, et al. Clinical performance evaluation of continuous glucose monitoring systems: a scoping review and recommendations for reporting. J Diabetes Sci Technol. 2023; 17(6): 1506- 1526. 37599389 PMC10658695 sourceExperimental — accuracy not yet measured
The Use of CGM Systems section reports a lack of head-to-head accuracy studies for most current CGM systems, supporting a narrower concern about limited comparative performance evidence. The paper does not establish that evidence is scarce specifically for non-iCGM-approved entrants, or that evidence is lacking for their glycemic outcomes, including time in, above, or below range and coefficient of variation. Page numbers were not available in our copy. (LLM, conf=0.79)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“By contrast, the manufacturers of many non-iCGM-approved devices sold outside the United States have not published robust accuracy data or randomized controlled trial data to support their use.”
§ Importance of FDA-Integrated Continuous Glucose Monitors to Ensure Accuracy of Continuous Glucose Monitoring > Conclusions
What the sources say
- Not checked yetcites [20] Rebec M Cai K Dutt-Ballerstadt R Anderson E. A prospective multicenter clinical performance evaluation of the C-CGM system. J Diabetes Sci Technol. 2022; 16(2): 390- 396. 33084416 PMC8861779 source
- Could not verifycites [21] Zhou J Zhang S Li L, et al. Performance of a new real-time continuous glucose monitoring system: a multicenter pilot study. J Diabetes Investig. 2018; 9(2): 286- 293. PMC5835467 28563974 sourceExperimental — accuracy not yet measured
Our copy never characterizes the published evidence base for non‑FDA/non‑iCGM‑approved devices sold outside the United States. The Introduction (p. ~1) says only that the three major producers (Medtronic MiniMed, Dexcom, Abbott) have been investigated in 'numerous clinical trials' and head‑to‑head comparisons, and the Methods > Ethics section notes the Medtrum system was CE‑marked in 2016, launched on the European market, and has not received FDA approval, with this multicenter study carried out to obtain Chinese FDA approval — a statement about one device, not the general claim of unpublished robust accuracy or randomized controlled trial data across 'many' manufacturers. Searches for 'not published accuracy data', 'randomized controlled trial', 'sold outside the United States', and 'limited clinical evidence' returned no passage addressing the claim, and the Discussion in fact reports published accuracy figures (MARD, agreement, EGA) for several systems, so nothing here supports or contradicts it. (LLM, conf=0.70)
- Could not verifycites [22] Meng R Gu T Yang F Liu J Sun Q Zhu D. Performance evaluation of the Glunovo® continuous blood glucose monitoring system in Chinese participants with diabetes: a multicenter, self-controlled trial. Diabetes Ther. 2021; 12(12): 3153- 3165. 34704201 PMC8586329 sourceExperimental — accuracy not yet measured
Our copy of the Glunovo trial contains no statement about manufacturers' publication record for devices sold outside the United States or about iCGM approval; the Introduction (p. 1-2) and Discussion only compare Glunovo's accuracy against published Dexcom G4/G6 and Medtrum A6 TouchCare figures and rtCGMS-vs-flash trials. Note also a terminology mismatch: the source uses 'isCGMS' for intermittently scanned (flash) CGM, not the FDA 'integrated CGM (iCGM)' designation the citing sentence relies on. Searches for 'manufacturers have not published robust accuracy data or randomized controlled trial data', 'limited published performance data', 'iCGM FDA approval', and 'domestically produced CGMS in China' returned nothing addressing the claim, so it can be neither confirmed nor contradicted from this paper. If anything, the paper cites multicenter accuracy studies of non-US devices (Zhou et al. ref 22; Medtrum A6 ref 2), but it makes no general assertion about unpublished data. (LLM, conf=0.70)
- Could not verifycites [23] Yan L Li Q Guan Q, et al. Evaluation of the performance and usability of a novel continuous glucose monitoring system. Int J Diabetes Dev Ctries. 2023; 43: 551- 558. sourceExperimental — accuracy not yet measured
Our copy of Yan et al. (2023) is a single multicenter, one-arm accuracy/usability trial of the SiJoy GS1 CGM (Shenzhen Sibionics) in Chinese adults; it nowhere addresses iCGM approval, FDA regulatory categories, or whether manufacturers of non-iCGM-approved devices sold outside the United States have published accuracy or randomized trial data. The nearest statements are the Introduction's 'Due to a lack of previous studies on GS1 CGM' and the Discussion limitations ('it was one-arm clinical trial without compare to other conventional blood glucose monitoring methods... Future real-world studies with large sample size and comparison with other CGMs are warranted'), which concern this one device and this study's own design, not the general manufacturer-publication claim. Searches performed: 'iCGM/FDA approval/integrated CGM regulatory', 'manufacturers have not published robust accuracy data randomized controlled trial', and 'lack of clinical evidence for other CGM systems'; no passage speaks to the claim, so it can be neither confirmed nor contradicted from our copy. (LLM, conf=0.70)
- Partly supportedcites [29] Freckmann G Eichenlaub M Waldenmaier D, et al. Clinical performance evaluation of continuous glucose monitoring systems: a scoping review and recommendations for reporting. J Diabetes Sci Technol. 2023; 17(6): 1506- 1526. 37599389 PMC10658695 sourceExperimental — accuracy not yet measured
Our copy supports only the general/adjacent part: the Accuracy section (p. ~1) states that the FDA iCGM special control requires clinical performance data while 'to obtain a Conformite Europeenne (CE) mark, which is necessary for product launch in most European countries, no dedicated requirements for the clinical CGM performance evaluations and its outcomes have been published,' and the Abstract/Conclusion report that crucial study-design and accuracy-reporting aspects 'are often not reported in sufficient detail to allow an informed interpretation' (e.g., <25% of studies reported confidence intervals; only six studies reported sensor lots). What it does not state is the claim's specific attribution: that manufacturers of many non-iCGM-approved devices sold outside the United States have failed to publish robust accuracy data, and there is no mention anywhere in our copy of randomized controlled trial data for such devices. The review covers published performance studies of 178 CGM systems irrespective of iCGM approval status or market, so the manufacturer-level and RCT-level parts of the sentence are unsupported by this source. (LLM, conf=0.65)
- Could not verifycites [33] Kolle J Eichenlaub M Mende J, et al. Performance assessment of three continuous glucose monitoring systems in adults with type 1 diabetes [published online ahead of print February 22, 2023]. J Diabetes Sci Technol. doi: 10.1177/19322968231159657. PMC11529083 37758681 sourceExperimental — accuracy not yet measured
Our copy never addresses whether manufacturers of non-iCGM-approved devices sold outside the United States have published robust accuracy data or randomized controlled trial data; the term 'iCGM' appears only in the Figure 2 caption (FDA 'integrated' CGM deviation requirements) and in reference 13 (Stephan et al., FDA iCGM accuracy compliance). The closest passages — Introduction (device selection: FL2 and ADX chosen 'because of their comparatively low costs in high-income settings and a lack of manufacturer-independent performance assessment in the scientific literature') and Discussion (FL2: 'this is the first manufacturer-independent performance evaluation of this widely used CGM system') — concern the absence of *independent* evaluations, not the absence of manufacturer-published accuracy or RCT data, and the paper in fact cites prior manufacturer-affiliated accuracy publications (Alva et al. 2022, MARD 9.2%; Ji et al. 2023, MARD 10.1% for ADX). Searches: 'manufacturer-published accuracy data / devices lacking regulatory approval', 'iCGM approval United States randomized controlled trial data', 'lack of robust accuracy data published by manufacturers, no RCTs, marketed outside the United States', 'integrated CGM FDA approval adjunctive use regulatory clearance Europe'. (LLM, conf=0.66)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
20 more claims
Create a free account to see all 44 claims and to verify the 73 references still open.
- It may state two separate claims as one. 17
- Probably not a substantial claim. 6
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CGM systems are generally nonadjunctive, meaning they do not require BGM confirmation for treatment decisions like insulin dosing or treating hypoglycemia, except in certain clinical situations (see BLOOD GLUCOSE MONITORING, above) (44-46).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [46]
Experimental — accuracy not yet measured
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Bolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System
Bailey, T., Bode, B. W., Christiansen, M. P., Klaff, L. J., & Alva, S. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0378 · Cited by 685 · cited 1×
“34 However, it is also essential that factory-calibrated devices be supported by robust accuracy data.”
6. Glycemic Targets: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s006 · Cited by 684
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623
Aleppo, G., Ruedy, K. J., Riddlesworth, T. D., Kruger, D. F., Peters, A. L., Hirsch, I., Bergenstal, R. M., Toschi, E., Ahmann, A. J., Shah, V. N., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2482 · Cited by 329 · cited 1×
“12-14 Many but not all CGM systems are nonadjunctive.”
Evaluating the Accuracy of Continuous Glucose-Monitoring Sensors
Kovatchev, B. P., Gonder-Frederick, L. A., Cox, D. J., & Clarke, W. L. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1922 · Cited by 312
7. Diabetes Technology: Standards of Care in Diabetes — 2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s007 · Cited by 301 · cited 1×
“6,14,15 An integrated continuous glucose monitoring system (iCGM) is intended to automatically measure glucose in bodily fluids continuously or frequently for a specified period of time.”
Klonoff, D. C., Wang, J., Rodbard, D., Kohn, M. A., Li, C., Liepmann, D., Kerr, D., Ahn, D., Peters, A. L., Umpierrez, G. E., et al. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221085273 · Cited by 295
Self-citation
Cited by
7. Diabetes Technology: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s007 · Cited by 348
Diabetes Technology Trends: A Review of the Latest Innovations
Lundgrin, E. L., Kelly, C. A., Bellini, N. J., Lewis, C. J., Rafi, E., & Hatipoğlu, B. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf034 · Cited by 36
Benhalima, K., Durnwald, C. P., Sweeting, A., Adams, D., Addala, A., Battelino, T., Bergenstal, R. M., Carlson, A. L., Donovan, L., Franco, D. R., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00335-3 · Cited by 37
Pleus, S., Eichenlaub, M., Dabla, P. K., Diem, P., Boija, E. E., Fokkert, M. J., Hinzmann, R., JENDLE, J. H., Klonoff, D. C., Lu, J., et al. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120728 · Cited by 26
Self-citationContinuous glucose sensor accuracy: beyond the headline metric
Oliver, N. S., Reddy, M., & Leelarathna, L. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00245-6 · Cited by 21
Metadata
- Authors
- Klonoff, D. C., Gabbay, M., Moon, S. J., & Wilmot, E. G.
- Affiliations
- Diabetes Research Institute, Mills-Península Medical Center, San Mateo, CA, USA
- UNIFESP—Federal University of Sao Paulo, Sao Paulo, Brazil
- Kangbuk Samsung Hospital (KR)
- University of Nottingham (GB)
- Corresponding author
- Klonoff, David C.
- Venue
- Journal of Diabetes Science and Technology
- Publisher
- SAGE Publications
- Published
- 2024-05-03
- Volume
- 19
- Issue
- 5
- Pages
- 1392-1399
- ISSN
- 1932-2968 (ISSN-L)
- PMC
- PMC11571640
- OpenAlex
- W4396592970
- Semantic Scholar
- 406c089a9342cb017f5d25eb4760dee7ccc19abf
- Cited by
- 36
- References
- 45
- Citations by year
- 2026: 19 · 2025: 14 · 2024: 3
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (vor)
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Diabetes Science and Technology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Repository@Nottingham (University of Nottingham) (acceptedVersion, other-oa)
- Funders
- Abbott Diabetes Care
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- continuous glucose monitoring, FDA clearance, CGM accuracy, diabetes management, insulin dose, hypoglycemia prevention, glycemic control, cost-effectiveness
- MeSH terms
- Continuous Glucose Monitoring, Blood Glucose, Diabetes Mellitus, Humans, United States, United States Food and Drug Administration, Blood Glucose Self-Monitoring, Device Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Importance of FDA-Integrated Continuous Glucose Monitors to Ensure Accuracy of Continuous Glucose Monitoring. https://app.cochat.ai/papers/10.1177/19322968241250357
- The paper
- Klonoff, D. C., Gabbay, M., Moon, S. J., & Wilmot, E. G. (2025). Importance of FDA-Integrated Continuous Glucose Monitors to Ensure Accuracy of Continuous Glucose Monitoring. Journal of Diabetes Science and Technology. https://doi.org/10.1177/19322968241250357
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.